On 31 October 2024, BIOSTAR PHARM-B(02563.HK) was successfully listed on the Main Board of the Hong Kong Stock Exchange, becoming the‘No.1 Synthetic Biology Pharmaceutical Stock’in the Hong Kong stock market.. BIOSTAR PHARM-B's global offering of 14,588,800 shares, priced at HK$16 per share, raised gross proceeds of approximately HK$230 million.

In this transaction, Tianyuan, DeHeng and HNP Law Firm PLLC jointly acted as legal advisers to the Issuer. Tianyuan acted as the Hong Kong legal advisor of the Issuer; Beijing Deheng acted as the PRC legal advisor of the Issuer and provided overseas legal services including legal due diligence of the Issuer's overseas shareholders for this project; and HNP Law Firm PLLC provided services to Huahao Zhongtian in respect of the relevant U.S. laws.

CCB International and CSCI acted as joint sponsors for the project, and Jingtian & Gongcheng acted as both the domestic and Hong Kong legal advisers to the sponsors and the underwriters.

Founded in 2002, BIOSTAR PHARM-B is a synthetic biology technology-driven biopharmaceutical company focused on developing innovative anti-tumour drugs using synthetic biology technology. It had submitted a listing application to the SSE in 2022 and withdrew the application in May the following year. Since then, Huahao Zhongtian has re-submitted its application to the HKSE twice, on 29 January 2024 and 12 August 2024 respectively. The funds raised from the IPO will mainly be used to fund clinical trials of its core products, strengthen its domestic marketing capabilities and establish a global marketing network, expand its production capacity, as well as for working capital and general corporate purposes.